highrisk
patient
requir
hospit
sever
acut
respiratori
syndrom
coronaviru
infect
year
old
male
obes
smoker
common
comorbid
includ
hypertens
cardiovascular
diseas
diabet
chronic
lung
diseas
immunocompromis
cancer
patient
also
greater
risk
one
metaanalysi
rel
risk
experienc
sever
versu
nonsever
diseas
higher
patient
hypertens
respiratori
diseas
cardiovascular
diseas
respect
use
angiotensinconvert
enzym
ace
inhibitor
angiotensin
receptor
blocker
arb
hypertens
heart
failur
diabet
may
upregul
express
latter
involv
bind
uptak
lung
epithelium
may
also
unregul
smoke
small
airway
epithelia
remain
unclear
whether
increas
risk
infect
attribut
hypertens
agerel
comorbid
per
se
current
hypertens
heart
failur
guidelin
advoc
stop
switch
ace
inhibitor
arb
upstream
therapeut
strategi
revolv
around
use
antivir
figur
one
studi
show
benefit
use
lopinavir
plu
ritonavir
standard
care
sick
hospit
adult
patient
sever
pneumonia
even
though
studi
like
underpow
turn
perhap
infer
use
upstream
antivir
therapi
alon
may
success
later
diseas
process
downstream
cytokin
avalanch
trigger
result
subsequ
lung
damag
said
compassion
use
iv
remdesivir
patient
sever
infect
result
improv
oxygen
statu
mortal
among
receiv
invas
ventil
albeit
control
arm
comparison
also
interest
use
azithromycin
includ
action
hyazout
trial
basi
immunomodulatori
put
antivir
activ
although
effect
remain
specul
caution
advis
trial
evalu
azithromycin
conjunct
hydroxychloroquin
due
potenti
addit
effect
qt
interv
prolong
propens
arrhythmia
block
viral
host
cell
entri
antimalari
drug
hydroxychloroquin
chloroquin
anoth
potenti
upstream
modal
figur
hydroxychloroquin
safer
potent
term
vitro
suppress
hydroxychloroquin
act
via
increas
endosom
ph
attenu
endocyt
host
cell
entri
lung
epithelium
hydroxychloroquin
shown
promis
preliminari
clinic
result
term
attenu
vivo
viral
load
includ
solidar
trial
well
nihr
recoveri
principl
trial
hydroxychloroquin
may
also
exhibit
downstream
immunosuppress
effect
reduc
product
cell
monocyt
may
explain
part
use
autoimmun
condit
date
one
non
peer
review
randomis
control
trial
franc
hydroxychloroquin
ad
usual
care
patient
sever
pneumonia
report
signific
impact
primari
end
point
intens
care
death
within
day
patient
stop
hydroxychlorquin
due
qt
prolong
bromhexin
overthecount
cough
remedi
block
receptormedi
viral
cell
entri
via
transmembran
proteas
serin
enzym
theoret
could
potenti
synergi
term
effect
block
viral
host
cell
entri
use
combin
hydroxychloroquin
bromhexin
present
remain
specul
remain
seen
whether
agent
like
effect
earli
diseas
given
prevent
upstream
viral
entri
littl
consider
appear
given
suscept
patient
obstruct
airway
diseas
regard
infect
particular
elderli
patient
chronic
obstruct
pulmonari
diseas
copd
impair
respiratori
reserv
plethora
comorbid
potenti
confer
pathophysiolog
pharmacolog
suscept
individu
high
risk
advers
outcom
result
sever
infect
patient
copd
take
inhal
corticosteroid
ic
combin
therapi
increas
pneumonia
risk
especi
lipophil
drug
fluticason
furoat
due
prolong
lung
retent
associ
local
immunosuppress
presenc
alter
lung
microbiom
impair
mucociliari
clearanc
moreov
suppress
interferon
fluticason
propion
associ
increas
bacteri
load
rhinoviru
infect
corticosteroid
may
also
attenu
product
antibacteri
protect
peptid
cathelicidin
lung
epithelium
thu
secondari
bacteri
infect
might
contribut
cumul
inflammatori
burden
addit
viral
pneumonia
caution
exercis
extrapol
copd
asthma
even
though
patient
copd
corticosteroid
respons
eosinophil
compon
henc
patient
copd
blood
eosinophil
cellsml
benefit
fluticason
furoat
reduc
sever
exacerb
outweigh
risk
induc
sever
pneumonia
nevertheless
one
canadian
cohort
studi
patient
asthma
demonstr
current
ic
use
associ
rel
increas
risk
pneumonia
amount
excess
case
per
patientyear
interestingli
ciclesonid
mometason
budesonid
beclomethason
fluticason
exhibit
vitro
suppress
replic
similar
degre
lopinavir
albeit
preliminari
non
peer
review
data
ciclesonid
target
viral
replic
appear
nonstructur
protein
budesonid
formoterol
independ
suppress
system
suppress
relat
acut
lung
injuri
mous
model
pointedli
asthmat
take
ic
less
like
sever
outcom
hospit
influenza
infect
perhap
infer
gener
protect
ic
class
effect
meantim
key
messag
patient
asthma
adher
ic
control
therapi
like
offer
best
protect
viral
insult
includ
junctur
evid
support
switch
patient
control
asthma
inhal
ciclesonid
mometason
studi
evalu
ciclesonid
south
figur
cytokin
cascad
result
acut
sever
infect
downstream
activ
consid
hallmark
featur
term
progress
pneumonia
hyperinflamm
ard
also
shown
put
mechan
action
bromhexin
hydroxychloroquin
attenu
upstream
tissu
bind
effect
antivir
replic
azithromycin
antivir
immunomudul
nonspecif
cytokin
suppress
corticosteroid
togeth
select
downstream
effect
blockad
tocilizumab
sarilumab
effect
antitnf
interferon
angiotensin
convert
enzym
acei
angiotensin
convert
enzym
inhibitor
arb
angiotensin
ii
receptor
blocker
ard
acut
respiratori
distress
syndrom
crp
c
reactiv
protein
sever
acut
respiratori
syndrom
coronaviru
tnf
tumour
necrosi
factor
transmembran
proteas
serin
korea
look
rate
erad
patient
mild
infect
anoth
studi
compar
high
dose
ciclesonid
usual
care
japan
report
progress
sever
covid
pneumonia
corticosteroid
may
consid
rather
blunt
tool
deal
cytokin
cascad
infect
exhibit
broadspectrum
suppress
effect
system
corticosteroid
part
routin
manag
acut
viral
exacerb
asthma
copd
effect
treat
eosinophil
compon
type
inflamm
corticosteroid
may
also
suppress
host
immun
respons
increas
viral
replic
revers
adjuv
interferon
studi
inhal
evalu
whether
upregul
lung
antivir
defens
effect
ill
wherea
trial
evalu
subcutan
lopinavirritonavir
one
might
postul
nebul
may
achiev
adequ
alveolar
drug
concentr
sever
infect
token
nebul
antibiot
effect
bacteri
pneumonia
infect
may
induc
profound
downstream
cytokin
cascad
involv
tnfa
figur
releas
cytokin
follow
rapid
develop
lung
tissu
damag
result
acut
respiratori
distress
syndrom
sepsi
organ
failur
may
requir
assist
ventilatori
support
extracorpor
membran
oxygen
one
non
peer
review
studi
sever
infect
found
risk
respiratori
failur
patient
maxim
circul
level
pgml
higher
median
time
mechan
ventil
day
select
approach
therefor
requir
address
downstream
cytokin
storm
recent
attent
center
around
possibl
therapeut
intervent
drug
tocilizumab
sarilumab
indic
rheumatoid
diseas
emerg
evid
may
also
use
repurpos
sever
infect
term
dampen
downstream
cytokin
respons
associ
hyperinflammatori
syndrom
latter
primarili
character
secondari
hemophagocyt
lymphohistiocytosi
compassion
use
uncontrol
non
peer
review
studi
china
patient
infect
use
agent
tocilizumab
show
rapid
reduct
fever
c
reactiv
protein
crp
oxygen
requir
along
improv
radiolog
appear
normal
lymphocyt
count
within
day
administr
singl
mg
dose
moreov
patient
discharg
within
mean
hospit
period
day
tocilizumab
patient
alreadi
routin
treatment
week
includ
lopinavir
methylprednisolon
receiv
tocilizumab
signific
limit
may
therefor
surviv
bia
sicker
patient
would
expect
rapidli
deterior
within
first
week
hospit
ill
evid
data
need
urgent
replic
ideal
random
control
trial
studi
way
recruit
hospit
patient
use
agent
sarilumab
wherea
studi
evalu
tocilizumab
alon
covacta
tocovid
combin
favipiravir
well
nihr
recoveri
trial
part
second
random
arm
would
advoc
patient
sever
infect
screen
biomark
hyperinflamm
includ
rise
crp
ferritin
ddimer
plasma
viscos
cytopenia
includ
fall
platelet
count
may
highlight
atrisk
patient
suppress
could
benefici
cogent
reason
suggest
combin
treatment
modal
might
requir
obviat
upstream
lung
tissu
bind
hydroxychloroquin
bromhexin
instead
antivir
togeth
downstream
blockad
sarilumab
tocilizumab
figur
mind
believ
studi
urgent
warrant
investig
combin
therapi
older
suscept
individu
comorbid
high
risk
develop
sever
pneumonia
ultim
indic
combin
therapi
determin
factor
stage
diseas
safeti
cost
rout
administr
sever
infect
poor
outcom
occur
older
suscept
patient
may
male
obes
smoker
multipl
comorbid
patient
eosinophil
asthma
copd
continu
use
icscontain
therapi
maintain
optim
control
protect
viral
insult
includ
infect
strategi
includ
antivir
therapi
lopinavirritonavir
block
viral
host
cell
entri
hydroxychloroquin
may
success
unless
use
earlier
cours
infect
sever
infect
may
produc
cytokin
storm
associ
hyperinflammatori
syndrom
hemophagocyt
lymphohistiocytosi
level
highli
predict
respiratori
failur
screen
biomark
hyperinflamm
cytopenia
crp
ddimer
plasma
viscos
ferritin
may
identifi
atrisk
patient
cytokin
suppress
may
benefici
clinic
trial
urgent
warrant
evalu
combin
therapeut
strategi
target
upstream
downstream
pathway
sever
diseas
